Exploring the Content Validity of Patient‐Reported Outcome Measures to Capture the Patient Experience of Becker Muscular Dystrophy Authors: Abby Bronson, Katie Mellor, Nicole Kilburn, Ryan Fischer, Natalie Aldhouse, Chris Marshall, Tamara Al‐zubeidi Published: 2026 ABSTRACT ABSTRACTIntroduction/AimsThe patient experience of Becker muscular dystrophy (BMD) is not well understood, making it difficult to evaluate the conceptual relevance of proposed patient‐reported outcome (PRO) measures. This study aimed to conceptualize the patient experience of BMD and evaluate content validity and perceptions of meaningful changes of PRO measures in this population.MethodsSemi‐structured interviews were conducted with ambulatory adult and adolescent US‐based participants with BMD. Transcripts were analyzed using content and framework analysis. Participant quotes were coded to identify concepts and themes, illustrated in a conceptual model of BMD experience. Cognitive debriefing methods assessed patient understanding of the brief pain inventory‐short form (BPI‐SF), quality of life in neurological disorders (Neuro‐QoL), and three patient‐reported outcomes measurement information system (PROMIS‐57) domains: Physical Function, Fatigue, and Pain Interference.ResultsTwenty‐nine patients (mean age: 27.0 years; mean age at BMD diagnosis: 15.1 years) and two caregivers described a wide range of signs, symptoms, and impacts. Physical fatigue, pain, weakness, and impacts on physical mobility and emotional wellbeing were considered most bothersome. The BPI‐SF Item 3 and PROMIS‐57 domains were well understood and relevant; however, the Neuro‐QoL Upper Extremity questionnaire demonstrated low conceptual relevance.DiscussionThe conceptual model illustrated the burden of living with BMD. The BPI‐SF Item 3 and evaluated PROMIS‐57 domains are considered content‐valid PRO measures in BMD, with most participants associating score improvements with meaningful changes to their health‐related quality of life. Abbreviations Becker muscular dystrophy brief pain inventory‐short form continuous positive airway pressure Duchenne and Becker muscular dystrophies Duchenne muscular dystrophy food and drug administration health‐related quality of life limb girdle muscular dystrophy quality of life in neurological disorders patient‐reported outcome patient‐reported outcomes measurement information system standard deviation X‐linked hypophosphatemia Introduction Becker muscular dystrophy (BMD), part of the spectrum of dystrophinopathies, is an X‐linked disorder characterized by progressive muscle weakness with a variable phenotype, age of onset and symptom severity. Individuals with BMD commonly experience ongoing muscle injury, resulting in loss of muscle and consequent weakness, particularly in the lower limbs and pelvic area. This can lead to difficulty walking, climbing stairs, frequent falls, and loss of independence. Most affected adults with BMD require mobility assistive devices [1, 2, 3, 4]. BMD has also been associated with cognitive impairment, fatigue, difficulty breathing, myalgia, and muscle weakness in the upper limbs, neck and other areas [5, 6]. For some patients, BMD‐associated cardiomyopathy or less frequently, respiratory failure, can shorten life expectancy [5, 7]. To date, limited research has focused solely on BMD patient experiences. There is no cure or specifically approved treatment for BMD; however, potential therapies are being tested in clinical trials [8, 9, 10]. Following best practice guidance from the U.S. Food and Drug Administration (FDA) [11, 12, 13, 14, 15] and health economics and outcomes research groups [16, 17], it is important to ensure that patient‐reported outcome (PRO) measures used in clinical trials are fit‐for‐purpose in the context of use and target population. This includes establishing content validity, to ensure that the PRO measure is understood, consistently interpreted, and assesses concepts that are relevant to patients with BMD. Score differences should also be meaningful and reflect differences in patients' experience of included concepts. This study aimed to develop a comprehensive understanding of the patient experience of BMD and develop a conceptual model of BMD symptoms and impacts that can guide the selection of appropriate PRO instruments in clinical trials. As a secondary objective, we explored the content validity and patient perception of meaningful score change of three PRO measures. Methods This study comprised semi‐structured interviews with adult and adolescent participants diagnosed with BMD. The study protocol was approved by the WCG Independent Review Board (20220963). A multi‐stakeholder steering committee, that included a patient advocate and a clinical expert in neuromuscular disease, provided feedback on the study design and interview guide, and supported the selection of PRO measures for inclusion, data interpretation and conceptual model development. Sample Eligible participants were US‐based patients aged 12–55 years with a diagnosis of BMD, or their caregivers. A sample of n = 24 participants was planned as previous research has suggested that 12–15 participants is usually the minimum sufficient to achieve conceptual saturation, defined as the point at which no new concept‐relevant information is reported [18], in a relatively homogenous sample [19]. All patients were ambulatory. Purposive sampling quotas were applied to include a range of ambulatory status, from those who could walk unaided to those who required assistance for short distances. Recruitment Participants were identified via an existing patient database (maintained by the sponsor of this research), a targeted email campaign by the patient organization Parent Project Muscular Dystrophy, and via two specialist recruitment agencies. Before taking part in an interview, adult participants provided written informed consent and adolescents provided written informed assent accompanied by caregiver informed consent. Participants either self‐reported their diagnosis or obtained confirmation from their treating clinician through a clinician‐completed case report form. Unique identifiers were sequentially assigned to participants during recruitment to maintain anonymity. Identifiers included the participant's ambulatory status: AM1: no walking aid/assistance required; AM2: required a walking aid/assistance sometimes; AM3: required a walking aid/assistance most of the time or always. Interview Procedures Remote interviews were conducted by four experienced researchers trained in qualitative interviewing. Interviewers followed a semi‐structured interview guide. Participants attended either two separate 45‐min concept elicitation and cognitive debriefing interviews or one combined 90‐min interview. Some participants, including solo‐caregivers, only attended the 45‐min concept elicitation interview. All adolescent participants were interviewed with their caregiver present; in the first phase (concept elicitation) the caregiver also participated as a dyad interview, but caregivers were not active participants in the second phase (cognitive debriefing). All interviews were audio‐recorded and transcribed verbatim. Concept elicitation interviews included exploratory open questions about BMD signs and symptoms, impacts, and unmet treatment needs. Supplementary probing questions were used to further explore concepts that had not been spontaneously discussed by participants to obtain a deep understanding of the patient experience. Participants were asked to rank each symptom they experienced on a 0 (no bother/does not disturb) to 10 (most bothersome/greatly disturbs) scale. Participants also ranked the five most bothersome impacts of living with BMD. In cognitive debriefing “read aloud” interviews, participants were asked to verbalize their thoughts as they completed three PRO measures. These measures had been identified from a targeted literature review conducted by the authors prior to conducting the interviews and were considered potentially relevant to capture the patient experience of BMD. Interviewers asked direct questions to establish understanding of each measure's instructions, questions, response options and recall period, and to obtain evidence of concept relevance. Interviewers also explored changes in item scores that participants considered meaningful, and the associated impacts of the score change. Three PRO measures were debriefed: Brief Pain Inventory‐Short Form (BPI‐SF) item 3: Assesses pain at its worst in the last 24 h [20, 21].Quality of Life in Neurological Disorders (Neuro‐QoL) upper extremity module: Evaluates fine motor and self‐care (activities of daily living) [22, 23].Patient‐Reported Outcomes Measurement Information System (PROMIS‐57): A set of generic PRO measures assessing physical, mental, and social health impacts across seven domains [24]. The Physical Function, Fatigue and Pain Interference domains were fully evaluated. The Pain intensity, Anxiety, Depression, Sleep Disturbance, and Social Roles and Activities domains were debriefed for comprehension and relevance only. Brief Pain Inventory‐Short Form (BPI‐SF) item 3: Assesses pain at its worst in the last 24 h [20, 21]. Brief Pain Inventory‐Short Form (BPI‐SF) item 3: Assesses pain at its worst in the last 24 h [20, 21]. Quality of Life in Neurological Disorders (Neuro‐QoL) upper extremity module: Evaluates fine motor and self‐care (activities of daily living) [22, 23]. Quality of Life in Neurological Disorders (Neuro‐QoL) upper extremity module: Evaluates fine motor and self‐care (activities of daily living) [22, 23]. Patient‐Reported Outcomes Measurement Information System (PROMIS‐57): A set of generic PRO measures assessing physical, mental, and social health impacts across seven domains [24]. The Physical Function, Fatigue and Pain Interference domains were fully evaluated. The Pain intensity, Anxiety, Depression, Sleep Disturbance, and Social Roles and Activities domains were debriefed for comprehension and relevance only. Patient‐Reported Outcomes Measurement Information System (PROMIS‐57): A set of generic PRO measures assessing physical, mental, and social health impacts across seven domains [24]. The Physical Function, Fatigue and Pain Interference domains were fully evaluated. The Pain intensity, Anxiety, Depression, Sleep Disturbance, and Social Roles and Activities domains were debriefed for comprehension and relevance only. Analysis Analysis of de‐identified interview transcripts was facilitated by ATLAS.ti v9 (ATLAS.ti Scientific Software Development GmbH, Berlin, Germany). Sample characteristics were reported descriptively (e.g., mean and standard deviation [SD], frequency, and percentage). Directed qualitative content analysis techniques [25, 26, 27] were used to identify concepts that provided an understanding of participants' experiences of BMD symptoms and impacts. Concepts were grouped into domains and illustrated in a novel conceptual model. Conceptual saturation [18], was evaluated following best practice recommendations [16]; transcripts were grouped into sets of five in the order that interviews were conducted, and spontaneously elicited concepts were compared between sets. Framework analysis [28] utilizing specific, pre‐defined codes was conducted to establish participant understanding, relevance, and interpretation of the instructions, response options, and recall period of PRO measures. Participant perspectives of meaningful change on PRO item scores were evaluated using a mixed‐method approach: analysis of quantitative changes in item scores that were considered meaningful and indicative of treatment success was supplemented with qualitative content analysis of descriptions of what the change would mean and any anticipated impacts on participants. Spontaneously reported adverse events were reported in line with FDA MedWatch guidance [29]. Results Sample Characteristics A total of 31 concept elicitation interviews were conducted (29 patient and two solo caregiver interviews), with 22 patients also completing cognitive debriefing interviews (Table S1). Note that the two solo‐caregiver interviews were conducted with the same caregiver who has two children with BMD; they discussed each child in a separate interview. Both children then later decided to participate in a solo‐adolescent‐interview to debrief the measures in the subsequent recruitment phase. The sample of patients was diverse in age, ranging from 13 to 55 years, with a broad range in age at diagnosis (1–46 years). Most patients identified as male, white, and not Hispanic or Latino. The sample also reflected varied levels of mobility, from individuals who could walk unaided to those requiring walking aids. At the time of interview, engagement with physical therapy and treatment varied, with many patients not currently receiving any treatment (see Tables 1 and S2). TABLE 1Demographic and clinical characteristics of patients who participated (or were described) in an interview.Patient demographic and clinical characteristics (N = 29) a Mean (SD) [range]AgeAge diagnosed with BMD (years)15.1 (11.4) [1–46]Age at time of interview (years)27.0 (13.8) [13–55]Age category n (%)Adolescent (aged 12–17 years)13 (45%)Adult (aged 18–55 years)16 (55%)Gender n (%) b Man27 (93.1)Non‐binary1 (3.4)Woman–male at birth1 (3.4)Race c n (%) b , c White28 (96.6)American Indian or Alaska native1 (3.4)Asian1 (3.4)Ethnicity n (%)Not hispanic or latino28 (96.6)Hispanic or latino1 (3.4)Highest level of education completed (reported for N = 16 adults only) n (%) b Bachelor's degree5 (31.3)High school diploma or equivalent5 (31.3)Graduate/Post‐graduate degree4 (25)Some college1 (6.3)Some high school, but no diploma1 (6.3)Ambulatory status n (%)AM112 (41.4)AM29 (31.0)AM38 (27.6)Abbreviations: AM1, no walking aid/assistance required; AM2, required a walking aid/assistance sometimes; AM3, required a walking aid/assistance most of the time or always; BMD, Becker muscular dystrophy; SD, standard deviation. a One caregiver participant was the parent of two adolescents with BMD; therefore, although n = 31 interviews were conducted these were in relation to n = 29 unique patient experiences of BMD. b Percentages may not add up to 100% due to rounding. c Not mutually exclusive. Demographic and clinical characteristics of patients who participated (or were described) in an interview. Abbreviations: AM1, no walking aid/assistance required; AM2, required a walking aid/assistance sometimes; AM3, required a walking aid/assistance most of the time or always; BMD, Becker muscular dystrophy; SD, standard deviation. One caregiver participant was the parent of two adolescents with BMD; therefore, although n = 31 interviews were conducted these were in relation to n = 29 unique patient experiences of BMD. Percentages may not add up to 100% due to rounding. Not mutually exclusive. Patient Experience of BMD Signs and Symptoms Participants described a wide range of signs and symptoms associated with their (or their child's) experience of BMD (Illustrative quotes presented in Table S3). Physical fatigue, pain, and weakness were most frequently reported and ranked most bothersome among adult and adolescent participants, regardless of their level of ambulation. Physical fatigue was described as a general experience of physical exhaustion that required frequent rest. Participants also described fatigue specifically in their legs. For some it was experienced frequently, often triggered by daily activity, and particularly burdensome in the evenings. Others experienced it seemingly randomly, with no clear onset or trigger. Pain was described using terms like “aching” and “sharp,” and was most frequently experienced in the back and legs. Most participants shared that overexertion, such as when walking “a lot” or when climbing stairs triggered their pain. However, similar to physical fatigue, some experienced pain unpredictably, without any clear link to physical activity. Weakness was described both as a general symptom and as a sensation experienced only in specific parts of the body, most frequently the arms and legs. Weakness was more commonly reported by participants with reduced ambulation, with few fully ambulatory individuals describing it. Other signs and symptoms reported included mental fatigue, muscle cramps/spasms (which many specified were exercise induced), muscle tightness, stiffness, impaired cognition, enlarged calves, knee buckling, and rhabdomyolysis‐associated nausea. The two caregivers typically described the same symptoms as reported directly by patients. However, nausea and dark‐colored urine associated with rhabdomyolysis were exclusively noted by caregivers. While only one adult participant reported experiencing cardiac complications related to BMD during the interview, others expressed concern about developing cardiac issues in the future. Patient Experience of BMD Impacts Participants described varied impacts across eight domains: Physical, emotional, lifestyle, work/school, travel, social, relationships and sleep (Illustrative quotes presented in Table S4). Participants ranked impacts to physical functioning, activities of daily living, and emotional wellbeing as most bothersome. Almost all participants reported challenges with physical functioning, including difficulty walking, climbing stairs, lifting or carrying heavy objects, standing from sitting, and frequent falls. To manage these challenges, some participants described carefully planning their routes, for example avoiding stairs in favor of elevators or step‐free access, and relying on mobility aids such as handrails or wheelchairs when traversing longer distances. Almost all participants reported impacts on emotional wellbeing, including feelings of sadness, depression, worry about the future, and frustration. Although emotional impacts were experienced across all levels of ambulation, some concepts, such as worry about the future, were more frequently reported by those who were more ambulatory. Many described feeling sad about the progressive nature of the disease, anticipating future loss of function, and the emotional toll of the potential inability to keep up with friends or give up hobbies. However, a small number of participants described coping with their condition with acceptance or a stoic outlook, focusing on the positives. Many participants described experiencing lifestyle impacts, including difficulty completing housework, maintaining personal hygiene, and engaging with previously enjoyed hobbies. These challenges required increased planning around daily routines. Impacts to work or school were also frequently reported; patients required absences, were unable to complete physical tasks at work, or were unable to obtain employment. Many also described impacts on social functioning such as needing to hide their condition from peers out of fear of social exclusion or rejection. Relationships with friends, family, and romantic partners were also described as impacted, with some adult participants sharing their decision not to have children due to the genetic nature of BMD. Several participants also described difficulty falling and staying asleep, and difficulties traveling (both locally and internationally), often due to a lack of accessibility. Conceptual Model and Saturation Analysis A novel conceptual model was developed based on the interview data to visually illustrate the patient experience of BMD (Figure 1). The model has three major domains: signs and symptoms, impacts, and clinical complications, and includes arrows to signify relationships between domains where reported by participants. The model also differentiates concepts experienced by participants of different ambulatory status, based on the interview data. A conceptual model of the patient experience of BMD A conceptual model of the patient experience of BMD, including the signs, symptoms and impacts reported in patient concept elicitation interviews. BMD, Becker muscular dystrophy. Conceptual saturation was achieved for most signs, symptoms and impacts reported by participants; a comprehensive understanding of the patient experience of BMD was obtained. Few concepts were only mentioned by one participant each (headache, numbness, restlessness, restless leg syndrome, dark colored urine and hoarse voice). Cognitive Debriefing of PRO Measures BPI‐SF Item 3 Participants generally understood and found BPI‐SF Item 3 relevant and usable (Figure 2). One participant reported that the item was “never relevant” because they had “never been in any pain with this Becker's” (Adult, AM2; Figure 3). The item was interpreted as intended, with no major issues reported regarding comprehension, relevance, or response options. No critical changes were suggested. PRO Item‐level comprehension A bar chart presenting item‐level comprehension data. Participants generally understood all items across all measures debriefed. BPI‐SF, Brief Pain Inventory‐Short Form; Neuro‐QoL, Quality of Life in Neurological Disorders; PRO, patient‐reported outcome; PROMIS‐57, Patient‐Reported Outcomes Measurement Information System. PRO Item‐level conceptual relevance. A bar chart presenting item‐level conceptual relevance. Most participants considered the BPI‐SF Item 3, PROMIS‐57 Physical Function and Fatigue and Pain Interference domains to be relevant (currently or previously). Relevance of the Neuro‐QoL Upper Extremity questionnaire was not demonstrated. BPI‐SF, brief pain inventory‐short form; Neuro‐QoL, quality of life in neurological disorders; PRO, patient‐reported outcome; PROMIS‐57, patient‐reported outcomes measurement information system. Generally, participants associated a 1‐point improvement from their current score on the BPI‐SF Item 3 with a meaningful improvement in their pain (Figure 4), allowing them to do more physical activities such as walking, which they associated with feeling happier (Table 2). Meaningful improvement in score on each PROa. Bar charts presenting meaningful change in PRO score. Across all measures, participants generally associated a 1‐point improvement from their current score with a meaningful improvement. aMeaningful change was not explored with participants who did not consider the item(s) to be relevant. BPI‐SF, brief pain inventory‐short form; Neuro‐QoL, quality of life in neurological disorders; PRO, patient‐reported outcome; PROMIS‐57, patient‐reported outcomes measurement information system. TABLE 2Qualitative understanding of a 1‐point meaningful improvement, at item level, on each measure.MeasureMeaningful improvement a Quotes to illustrate what a 1‐point improvement on the referenced item would meanBPI‐SF Item 31‐point (n = 12/20, 60%) − “I would feel good about that, because a lot of times, that's the one thing that's slowing you down. You know, with – you know, “pain,” you tend to walk a different way. You, you tend to be a lot stiffer, because you don't like to feel the pain and, err, yeah, I would say that any kind of improvement would be better” (Adult, AM3) Neuro‐Qol‐upper extremity questionnaire1‐point (n = 15/17, 88%) − “It would make me feel better that I could do it more often without any difficulty just cause you have to do it every day and it's – if you're struggling with it, it's, kind of, annoying and just adds more time to your morning routine that just frustrates you.” (Adult, AM2 [quote relates to item 6]) PROMIS‐57: Physical function domain1‐point (n = 18/22, 82%) − “That would be incredible. Like, I would feel so much stronger. I would feel I could do so many more things. You know, even if it is just a little bit more walking, I – that would make me feel so much better.” (Adolescent, AM3 [quote relates to item 3]) PROMIS‐57: Fatigue domain1‐point (n = 17/20, 85%) − “I'd feel really good. I don't like feeling rundown and I like to have a lot of energy and it'd be nice to feel like, you know, nothing's in the way and you can, you can do things without feeling like that.” (Adult, AM2 [quote relates to item 3]) PROMIS‐57: Pain Interference domain1‐point (n = 16/17, 94%) − “I'm thinking a lot about – you know, similar to the previous questions with, like, being able to walk or do activities. I think if my pain were not interfering at all or just not present, that would be really, really huge. I think my pain is part of the reason why I think I have limits to some activities, and so, if that pain was not there, that would be a really, really significant difference. […] I think there really is an emotional toll that, that chronic pain does, does to a person, and so, I think, yeah, that would be a really, um, really good thing for my, for my mood.” (Adult, AM3 [quote relates to item 1]) Abbreviations: AM2, required a walking aid/assistance sometimes; AM3, required a walking aid/assistance most of the time or always; BPI‐SF, brief pain inventory‐short form; Neuro‐QoL, quality of life in neurological disorders; PROMIS‐57, patient‐reported outcomes measurement information system. a Meaningful change was not explored with participants who did not consider the item(s) to be relevant. Qualitative understanding of a 1‐point meaningful improvement, at item level, on each measure. − “I would feel good about that, because a lot of times, that's the one thing that's slowing you down. You know, with – you know, “pain,” you tend to walk a different way. You, you tend to be a lot stiffer, because you don't like to feel the pain and, err, yeah, I would say that any kind of improvement would be better” (Adult, AM3) “I would feel good about that, because a lot of times, that's the one thing that's slowing you down. You know, with – you know, “pain,” you tend to walk a different way. You, you tend to be a lot stiffer, because you don't like to feel the pain and, err, yeah, I would say that any kind of improvement would be better” (Adult, AM3) − “It would make me feel better that I could do it more often without any difficulty just cause you have to do it every day and it's – if you're struggling with it, it's, kind of, annoying and just adds more time to your morning routine that just frustrates you.” (Adult, AM2 [quote relates to item 6]) “It would make me feel better that I could do it more often without any difficulty just cause you have to do it every day and it's – if you're struggling with it, it's, kind of, annoying and just adds more time to your morning routine that just frustrates you.” (Adult, AM2 [quote relates to item 6]) − “That would be incredible. Like, I would feel so much stronger. I would feel I could do so many more things. You know, even if it is just a little bit more walking, I – that would make me feel so much better.” (Adolescent, AM3 [quote relates to item 3]) “That would be incredible. Like, I would feel so much stronger. I would feel I could do so many more things. You know, even if it is just a little bit more walking, I – that would make me feel so much better.” (Adolescent, AM3 [quote relates to item 3]) − “I'd feel really good. I don't like feeling rundown and I like to have a lot of energy and it'd be nice to feel like, you know, nothing's in the way and you can, you can do things without feeling like that.” (Adult, AM2 [quote relates to item 3]) “I'd feel really good. I don't like feeling rundown and I like to have a lot of energy and it'd be nice to feel like, you know, nothing's in the way and you can, you can do things without feeling like that.” (Adult, AM2 [quote relates to item 3]) − “I'm thinking a lot about – you know, similar to the previous questions with, like, being able to walk or do activities. I think if my pain were not interfering at all or just not present, that would be really, really huge. I think my pain is part of the reason why I think I have limits to some activities, and so, if that pain was not there, that would be a really, really significant difference. […] I think there really is an emotional toll that, that chronic pain does, does to a person, and so, I think, yeah, that would be a really, um, really good thing for my, for my mood.” (Adult, AM3 [quote relates to item 1]) “I'm thinking a lot about – you know, similar to the previous questions with, like, being able to walk or do activities. I think if my pain were not interfering at all or just not present, that would be really, really huge. I think my pain is part of the reason why I think I have limits to some activities, and so, if that pain was not there, that would be a really, really significant difference. […] I think there really is an emotional toll that, that chronic pain does, does to a person, and so, I think, yeah, that would be a really, um, really good thing for my, for my mood.” (Adult, AM3 [quote relates to item 1]) Abbreviations: AM2, required a walking aid/assistance sometimes; AM3, required a walking aid/assistance most of the time or always; BPI‐SF, brief pain inventory‐short form; Neuro‐QoL, quality of life in neurological disorders; PROMIS‐57, patient‐reported outcomes measurement information system. Meaningful change was not explored with participants who did not consider the item(s) to be relevant. Neuro‐QoL–Upper Extremity Questionnaire Although the Neuro‐QoL–Upper Extremity Questionnaire appears to be understood and usable (Figure 2), its relevance to the patient experience of BMD was not demonstrated (Figure 3). One item (item 4) was flagged by one adolescent as difficult to interpret due to contextual ambiguity related to table height and whether “bending” was required. Item relevance (at the time of the interview, or previously) varied widely; for every item, relevance was unclear for at least a quarter of the participants (Figure 3). One item (item 3), was only (previously) relevant to one adult participant, who had with limited ambulation. On the Neuro‐QoL—Upper Extremity module, most participants described that a 1‐point improvement would represent a meaningful change (Figure 4), allowing the completion of daily activities without the need to ask for help or needing to take breaks. PROMIS‐57: Physical Function Domain Participants generally appeared to understand the PROMIS‐57: Physical Function domain item instructions and response options, but a small number experienced difficulty understanding some individual items (items 1, 2 and 5; Figure 2). Every item was considered relevant (either currently or previously) to at least three quarters of participants (Figure 3). While some item modifications were suggested by participants, none were considered critical for completion. Participants generally considered a 1‐point improvement as meaningful (Figure 4), describing how they felt it would allow them to feel stronger, exercise more, and “do more things around the house,” for example carrying groceries or “picking things up from the floor”. PROMIS‐57: Fatigue Domain A small number of adolescent participants experienced difficulty with item understanding (items 1 and 3; Figure 2); they were unsure whether they should consider both physical and mental fatigue, and one participant noted that they were not familiar with the term “run‐down” in relation to fatigue. Every item was considered relevant (either currently or previously) to at least three quarters of participants (Figure 3). The response options and recall period were largely understood and usable, and no suggested changes were considered critical to completion of the domain. Participants generally considered a 1‐point improvement as meaningful (Figure 4), due to increased energy making it possible to “get things done,” leading to reduced worry about feeling tired. PROMIS‐57: Pain Interference Domain All participants demonstrated understanding of the PROMIS‐57: Pain Interference domain instructions, response options and recall period (Figure 2). Item relevance (either currently, or previously) varied, with items 6 and 8 considered least relevant to the patient experience of BMD. While some item modifications were suggested by participants, none were considered critical for completion. Participants reported that a 1‐point improvement would be a meaningful change in their experience of pain (Figure 4), describing how it would allow them to accomplish more when completing their daily activities, leading to improved mood and less anxiety. Top‐Line Debrief of Remaining PROMIS Domains The five remaining PROMIS‐57 domains—Pain Intensity, Anxiety, Depression, Sleep Disturbance and Ability to Participate in Social Roles and Activities—were debriefed as time allowed by a minimum of 17 participants. No difficulties were observed or reported, suggesting full understanding of the item wording and of the response scale. Of these domains, the Pain Intensity domain was considered most relevant to BMD. Discussion This study highlights a large burden of illness in BMD, encompassing physical, emotional and social impacts. A conceptual model was developed to highlight the symptoms and impacts that patients find most bothersome/salient. Previous research exploring coping strategies utilized by young adults with Duchenne muscular dystrophy (DMD) and BMD highlighted negative emotions and feelings of “being different” are common in this population [30]. Our findings further evidence the negative impact of BMD on emotional wellbeing, with sadness, depression, worry about the future, and frustration identified as highly bothersome experiences. Consistent with previous research exploring pain and activity limitations in children with DMD or BMD [31], participants described pain as a salient symptom, associated with impacts on daily activities, lifestyle, (school)work, and travel. Our research revealed some previously undescribed symptoms and impacts that were experienced by patients of lower ambulatory status, for example “opening doors.” Further research is needed to confirm the relevance of these concepts across different disease severity levels in BMD. Although the development and validation of PRO measures in neuromuscular diseases has been broadly explored [32], and the suitability has been evaluated in other slowly progressive neuromuscular diseases, including limb girdle muscular dystrophy (LGMD) [33, 34], limited evidence exists to support the use of these PRO measures in ambulant patients with BMD specifically. FDA best practice guidance prioritizes establishing content validity in the population of interest before assessing other measurement properties of PRO measures intended to be included in clinical trials [11]. Although the PROMIS‐57 and BPI are well‐established measures that have been validated for use in many indications including DMD [35] and X‐linked hypophosphatemia (XLH) [36], there is no evidence of their validity in an ambulatory BMD population. These findings support the content validity of the BPI‐SF Item 3 and the PROMIS‐57 Physical Function, Fatigue and Pain Interference domains for the assessment of key salient concepts in adolescent and adult BMD populations. No notable differences in conceptual relevance or patient understanding were observed between age groups or categories of ambulatory status. The content validity of the PROMIS‐57 Pain Interference domain is further supported by findings from a previous registry study of patients with BMD; patients completing the measure frequently reported experiencing interference of pain on their enjoyment of life and their day‐to‐day activities [37]. Conversely, despite documented BMD impairment on upper extremity function and patient reports in this study of impaired upper extremity function [38] (e.g., difficulty lifting heavy objects) (Figure 1), these findings suggest that the Neuro‐QoL Upper Extremity questionnaire is not suitable to capture the ambulatory patient experience of BMD due to the low relevance of the majority of item concepts. Limitations A small number of symptoms, including headache, numbness, restlessness, restless leg syndrome, dark colored urine, and hoarse voice, were only mentioned by one participant, suggesting that conceptual saturation was not achieved. The large sample size that informed saturation analysis [19] indicates that these infrequently reported concepts might be unique to individual patient experiences rather than as a reflection of the broader experience of BMD. For example, myoglobinuria (dark colored urine) has previously been described as a presenting symptom of BMD [39], and therefore might be experienced only by patients with higher ambulatory status in earlier stage of disease progression. This sample only included patients with BMD who were ambulatory which might explain why only one participant reported experiencing cardiac issues. Existing literature indicates that most individuals with BMD have asymptomatic cardiac involvement, with most patients experiencing skeletal muscle impairment and decreasing ambulation before the onset of cardiac symptoms [40]. Further, patients were not asked whether they were using continuous positive airway pressure (CPAP) or alternative ventilatory treatment which might have impacted their QoL experience. All participants in this study were based in the US and predominantly identified as non‐Hispanic White. Centers for Disease Control and Prevention data has shown that Duchenne and Becker muscular dystrophies (DBMD) are more prevalent in Hispanic individuals who were underrepresented [41]. This increased prevalence might be influenced by genetic factors as well as access to healthcare, with Black and Hispanic DBMD patients often diagnosed later than non‐Hispanic White patients [42]. These findings should therefore be confirmed in other countries and cultures. Finally, BMD diagnosis via genetic testing was not confirmed for all patients, with self‐reported diagnosis accepted. Comorbidities were also not explored, which may have a possible influence on the results. Conclusion This interview study provided in‐depth insights into the diverse experiences of ambulatory patients living with BMD and identified areas of unmet treatment need. The Neuro‐QoL Upper Extremity questionnaire is not considered suitable to capture the ambulatory patient experience of BMD due to the low relevance of item concepts. The BPI‐SF Item 3, and the PROMIS‐57 Physical Function, Fatigue and Pain Interference domains, were well understood by both adults and adolescents with BMD, and captured concepts that patients considered to be relevant demonstrating content validity. These measures may therefore be suitable to support patient‐focused endpoints in BMD clinical trials. Author Contributions Abby Bronson: conceptualization, writing – review and editing. Katie Mellor: conceptualization, investigation, writing – original draft, writing – review and editing, methodology, software, data curation. Tamara Al‐zubeidi: conceptualization, writing – original draft, writing – review and editing, methodology, software, data curation, investigation. Nicole Kilburn: writing – review and editing. Chris Marshall: conceptualization, writing – review and editing, methodology. Ryan Fischer: writing – review and editing. Natalie Aldhouse: conceptualization, writing – review and editing, methodology, software, data curation. Funding This work was supported by Edgewise Therapeutics, Boulder, Colorado, USA. Ethics Statement We confirm that we have read the Journal's position on issues involved in ethical publication and affirm that this report is consistent with those guidelines. Conflicts of Interest Abby Bronson and Nicole Kilburn are employees and stockholders of Edgewise Therapeutics. Ryan Fischer is an employee of Foundation for Angelman Syndrome Therapeutics, and is a former employee of Parent Project Muscular Dystrophy. Tamara Al‐zubeidi and Chris Marshall are employees and stockholders of Clarivate. Katie Mellor is an employee of Clarivate. Natalie Aldhouse was an employee and stockholder of Clarivate at the time this research was conducted. Supporting information Table S1: Number and type of participant in each interview. Table S2: Current and past treatments. Table S3: Signs/symptoms reported. Table S4: Impacts reported.